Quaternary Structure: Complexes |
Interleukin-1 receptor, type I |
Interleukin-33 receptor |
Interleukin-36 receptor |
Interleukin-1 receptor, type II |
Quaternary Structure Comments |
IL1RAP is an accessory protein subunit of the functional receptors for IL-1, IL-33 and IL-36. It is a component in three signalling pathways that involve six IL-1 family cytokines (IL-1α, IL-1β, IL-33, IL-36α, IL-36β and IL-36γ). |
Gene and Protein Information | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | References |
Human | - | 550 | 3q28 | IL1RAP | interleukin 1 receptor accessory protein | |
Mouse | - | 550 | 16 18.21 cM | Il1rap | interleukin 1 receptor accessory protein | |
Rat | - | 550 | 11q22 | Il1rap | interleukin 1 receptor accessory protein |
Previous and Unofficial Names |
IL1R3 |
IL-1R3 |
Database Links | |
Alphafold | Q9NPH3 (Hs), Q61730 (Mm), Q63621 (Rn) |
CATH/Gene3D | 2.60.40.10, 3.40.50.10140 |
ChEMBL Target | CHEMBL4804256 (Hs), CHEMBL4665591 (Hs) |
Ensembl Gene | ENSG00000196083 (Hs), ENSMUSG00000022514 (Mm), ENSRNOG00000001928 (Rn) |
Human Protein Atlas | ENSG00000196083 (Hs) |
OMIM | 602626 (Hs) |
Pharos | Q9NPH3 (Hs) |
UniProtKB | Q9NPH3 (Hs), Q61730 (Mm), Q63621 (Rn) |
Wikipedia | IL1RAP (Hs) |
Protein Comments |
An anti-IL1RAP monoclonal antibody (CAN04, nidanilimab) has been designed by Cantargia as a novel immunomodulator and it is being evaluated for potential antineoplastic efficacy in patients with solid malignant tumours (Phase 1/2 NCT03267316). CAN04 activates the immune system's killer cells and blocks proliferation signals that promote tumour growth. MAB-hR3, an antagonistic monoclonal antibody that targets IL1RAP inhibits signalling via all three of the signalling pathways in which IL1RAP is a co-receptor, is predicted to offer a novel broad spectrum anti-inflammatory agent for potential treatment of autoimmune and inflammatory diseases, with preclinical evidence provided by a mouse equivalent to MAB-hR3 which attenuates inflammation in in vivo models of inflammatory diseases that are driven by distinct subsets of the IL-1 family cytokines [1]. |
1. Højen JF, Kristensen MLV, McKee AS, Wade MT, Azam T, Lunding LP, de Graaf DM, Swartzwelter BJ, Wegmann M, Tolstrup M et al.. (2019) IL-1R3 blockade broadly attenuates the functions of six members of the IL-1 family, revealing their contribution to models of disease. Nat Immunol, 20 (9): 1138-1149. [PMID:31427775]
IL-1 receptor accessory protein. Last modified on 26/08/2019. Accessed on 13/11/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetomalariapharmacology.org/GRAC/ObjectDisplayForward?objectId=1897.